Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: Registry analysis by the international Radioimmunotherapy Network

Journal of Nuclear Medicine

Volumn 52, Issue 9, 2011, Pages 1354-1360

  Hohloch, Karin ^a   Delaloye, Angelika Bischof ^b   Windemuth Kieselbach, Christiane ^c   Gómez Codina, Jose ^d   Linkesch, Werner ^e   Jurczak, Woijciech ^f   Cacchione, Roberto ^g   Suh, Cheolwon ^h   Zinzani, Pier Luigi ⁱ   Trümper, Lorenz ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c ALCEDIS GMBH   (Germany)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f JAGIELLONIAN UNIVERSITY   (Poland)

^g CEMIC   (Argentina)

^h Ulsan College   (South Korea)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

B cell lymphoma; Radioimmunotherapy; Registry; RIT Network; Treatment

Indexed keywords

HEMOGLOBIN; IBRITUMOMAB TIUXETAN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER RADIOTHERAPY; CLINICAL OBSERVATION; DATA BASE; DISEASE SEVERITY; FEMALE; FOLLICULAR LYMPHOMA; GERMANY; HUMAN; INTERNET; LEUKOCYTE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REGISTER; SURVIVAL TIME; THROMBOCYTE; TREATMENT INDICATION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 80052609494     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.089920     Document Type: Article

References (17)

1. Ahmed S, Winter JN, Gordon LI, Evens AM. Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. Leuk Lymphoma. 2010;51:1163-1177.
2. Heinzelmann F, Engelhard M, Ottinger H. Follicular lymphoma: the role of radiotherapy for stages I and II. Strahlenther Onkol. 2010;186:191-196.
3. Liu Q, Fayad L, Cabanillas F. Improvement of overall and failure free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas MD Anderson Cancer Center. J Clin Oncol. 2006;24:1582-1589. (Pubitemid 46638782)
4. Fischer RI, LeBlanc M, Press OW. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447-8452.
5. Gallagher CJ, Gregory WM, Jones AE. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986;4:1470-1480. (Pubitemid 17183570)
6. Johnson PW, Rohatiner AZ, Whelan JS. Patterns of survival in patients with recurrent follicular lymphoma: a 20 year study from a single center. J Clin Oncol. 1995;13:140-147.
7. Connors JM. Radioimmunotherapy: hot new treatment for lymphoma. N Engl J Med. 2005;352:496-498. (Pubitemid 40175977)
8. Witzig TE, Gordon LI, Cabanillas F. Randomized controlled trial of yttrium-90-labeled ibritumumab tuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463. (Pubitemid 34525730)
9. Gopal AK, Gooley TA, Maloney DG. High dose radioimmunotherapy versus conventional high dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351-2357. (Pubitemid 37193569)
10. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long term follow up of the University of Michigan experience. Blood. 2000;96:1259-1266.
11. Fisher RI, Kaminski MS, Wahl RL. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565-7573. (Pubitemid 46291820)
12. Witzig TE, Molina A, Gordon LI. Long term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804-1810. (Pubitemid 46668544)
13. Mark S. Kaminski, M.D., Melissa Tuck, M.A. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
14. Morschhauser F, Radford J, Van Hoof A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156-5164.
15. Dreyling M, Trümper L, Von Schilling C. Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma-role of radioimmunotherapy. Ann Hematol. 2007;86:81-87. (Pubitemid 44963998)
16. Witzig TE, Flinn IW, Gordon LI. Treatment with ibritumomab tiutexan radio-immunotherapy in patients with rituximab refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269. (Pubitemid 34831524)
17. Morschhauser F, Illidge T, Huglo D. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54-58. (Pubitemid 47026818)